Date: 2015-05-20
Type of information: Licensing agreement
Compound: NKG2D receptor modulators
Company: Janssen Biotech, a J&J company (USA - NJ) Novo Nordisk (Denmark)
Therapeutic area: Autoimmune diseases
Type agreement: licensing
Action mechanism:
Disease: autoimmune diseases
Details: * On May 20, 2015, Novo Nordisk has signed an agreement with Janssen Biotech, under which Janssen will acquire an exclusive global licence to further develop and commercialise a clinical programme focused on therapy within autoimmune diseases. The programme targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement have not been disclosed. The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission.
Financial terms:
Latest news:
